Myeloid and Monocytic Leukemia, Phase I

Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia

Volunteers
Health Professionals

What is the purpose of this trial?

The safety, tolerability, and antileukemic response of ziftomenib in combination with standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the following agents: FLAG-IDA, low-dose cytarabine, and gilteritinib.

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Farah Fasihuddin

farah.fasihuddin@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Amer Zeidan, MBBS
Professor of Internal Medicine (Hematology); Chief, Hematologic Malignancies; Director, Early Therapeutics Research, Hematology; Leader, Clinical Research Team for Leukemias and Myeloid Malignancies, Yale Cancer Center; Chair, Protocol Review Committee (PRC) I, Yale Cancer Center; Assistant Medical Director, Clinical Trials Office (CTO), Yale Cancer Center; Director, Hematology Research Seminar Series, Hematology; Member, Executive Committee, Yale Cancer Center; Member, Clinical Trials Advisory Committee (CTAC), Yale Cancer Center

Sub-Investigators

Last Updated
08/06/2024
Study HIC
#2000035900